drugset
drugset / Trial / NCT02666196

A Single Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Orally Administered DAA-I in Healthy Subjects

NCT02666196 ↗

Phase 1 Completed 18 enrolled National University Hospital, Singapore
RandomizedSingle-groupSingle-blind

Summary

This is a placebo-controlled randomized phase 1 study to investigate the safety and pharmacokinetics of DAA-I in a cohort of healthy subjects.

Timeline

Start
2015-09
Primary completion
2015-12
Completion
2015-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject DAA-I Peptide 0.08 mg/kg Oral
Subject DAA-I Peptide 0.7 mg/kg Oral
Subject DAA-I Peptide 1.5 mg/kg Oral

Indications

No indication recorded.